The global peptide therapy market is undergoing an unprecedented structural transformation driven by the GLP-1 revolution -- the extraordinary commercial success of glucagon-like peptide-1 receptor agonist drugs for diabetes and obesity. The market was worth USD 84.2 billion in 2025 and is expected to grow at a CAGR of 14.74% to reach USD 196.5 billion by 2031. Peptide therapeutics are on track to surpass oncology as the world's largest therapeutic market category by 2028-2030 -- making this the fastest-growing major drug class in pharmaceutical history.
The market's dominant force is the GLP-1/GIP Receptor Agonist Therapy segment, accounting for 65.8% of global peptide market value, growing at 16.43% CAGR by value and 23.95% by volume through 2031. This segment is led by a duopoly: Novo Nordisk's semaglutide (Ozempic, Wegovy) and Eli Lilly's tirzepatide (Mounjaro, Zepbound).
China's 140 million type 2 diabetics, India's rapidly expanding middle class, and Japan's aging population collectively represent the most important geographic growth opportunity. India's emergence as both a high-growth demand market (19.89% CAGR) and a biosimilar manufacturing hub creates a unique dual role in this market's evolution.
The market's dominant force is the GLP-1/GIP Receptor Agonist Therapy segment, accounting for 65.8% of global peptide market value, growing at 16.43% CAGR by value and 23.95% by volume through 2031. This segment is led by a duopoly: Novo Nordisk's semaglutide (Ozempic, Wegovy) and Eli Lilly's tirzepatide (Mounjaro, Zepbound).
China's 140 million type 2 diabetics, India's rapidly expanding middle class, and Japan's aging population collectively represent the most important geographic growth opportunity. India's emergence as both a high-growth demand market (19.89% CAGR) and a biosimilar manufacturing hub creates a unique dual role in this market's evolution.
Scope of Global Peptide Therapy Market Strategic Research Report 2026-2031
- This report provides forecast data by value for the global peptide therapy market, with 2025 as the base year and forecasting to 2031.
- This report provides segmentation by therapy class (GLP-1/GIP Receptor Agonists, Oncology Peptides, Cardiovascular, Other) and by indication.
- This report provides region-wise and country-level forecast data.
- This report identifies key growth drivers and inhibitors, including the GLP-1 revolution.
- This report provides company profiles for the leading peptide therapy companies including the Novo Nordisk/Eli Lilly duopoly.
- This report provides Porter's Five Forces, PESTLE, and SWOT analysis.
- This report identifies key future trends through 2031.
Who can use the Global Peptide Therapy Market Research Report?
This research report is ideal for people who wish to gain a thorough understanding of the peptide therapy market. Some of the intended users are:
- C-level executives and Company Directors in pharmaceutical companies
- Investment managers, Financial professionals, and Venture Capitalists
- Anyone operating in the peptide therapeutics value chain.
Table of Contents
1. Executive Summary
Scope of Global Peptide Therapy Market Strategic Research Report 2026-2031
Research Methodology
Research Methodology
2. Forecast for Global Peptide Therapy Market 2026-2031
2.1 Overall Global Peptide Therapy Market Forecast 2026-2031 by Value (in USD billion)
2.2 Overall Global Peptide Therapy Market Forecast 2026-2031 by Volume (in Billion Dosage Units)
2.2 Overall Global Peptide Therapy Market Forecast 2026-2031 by Volume (in Billion Dosage Units)
3. Segment by Type Market Share in Global Peptide Therapy Market 2026-2031
3.1 Global GLP-1/GIP Receptor Agonist Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
3.2 Global Somatostatin Analog Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
3.3 Global LHRH Analog / GnRH Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
3.4 Global Hormonal Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
3.5 Global Immunomodulatory Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
3.6 Global Bone & Growth Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
3.7 Global Oncology Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
3.8 Global Other Peptide Therapies Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
3.2 Global Somatostatin Analog Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
3.3 Global LHRH Analog / GnRH Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
3.4 Global Hormonal Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
3.5 Global Immunomodulatory Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
3.6 Global Bone & Growth Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
3.7 Global Oncology Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
3.8 Global Other Peptide Therapies Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
4. Segment by Application Market Share in Global Peptide Therapy Market 2026-2031
4.1 Global Diabetes & Obesity Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
4.2 Global Oncology (Cancer Treatment) Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
4.3 Global Endocrinology Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
4.4 Global Reproductive Health & Urology Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
4.5 Global Immunology & Transplant Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
4.6 Global Bone Metabolism & Mineral Disorders Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
4.7 Global Rare Diseases & Orphan Conditions Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
4.8 Global Other Applications Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
4.2 Global Oncology (Cancer Treatment) Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
4.3 Global Endocrinology Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
4.4 Global Reproductive Health & Urology Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
4.5 Global Immunology & Transplant Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
4.6 Global Bone Metabolism & Mineral Disorders Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
4.7 Global Rare Diseases & Orphan Conditions Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
4.8 Global Other Applications Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5. Region-Wise Market Share in Global Peptide Therapy Market 2026-2031
5.1 Asia-Pacific Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.1.1 China Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.1.2 Japan Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.1.3 India Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.1.4 South Korea Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.1.5 Australia Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.1.8 Rest of Asia Pacific Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.2 North America Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.2.1 USA Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.2.2 Canada Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.3 Europe Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.3.1 Germany Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.3.2 France Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.3.3 United Kingdom Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.3.4 Italy Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.3.5 Spain Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.3.6 Rest of Europe Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.4 Middle East & Africa Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.4.1 Saudi Arabia Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.4.2 UAE Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.4.3 Israel Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.4.4 South Africa Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.4.5 Turkey Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.4.6 Rest of Middle East & Africa Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.5 Latin America Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.5.1 Brazil Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.5.2 Mexico Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.5.3 Argentina Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.5.4 Colombia Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.5.5 Rest of Latin America Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.6 Top 15 Countries in Peptide Therapy Market by 2031 Value (in USD billion)
5.1.1 China Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.1.2 Japan Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.1.3 India Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.1.4 South Korea Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.1.5 Australia Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.1.8 Rest of Asia Pacific Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.2 North America Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.2.1 USA Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.2.2 Canada Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.3 Europe Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.3.1 Germany Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.3.2 France Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.3.3 United Kingdom Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.3.4 Italy Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.3.5 Spain Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.3.6 Rest of Europe Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.4 Middle East & Africa Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.4.1 Saudi Arabia Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.4.2 UAE Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.4.3 Israel Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.4.4 South Africa Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.4.5 Turkey Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.4.6 Rest of Middle East & Africa Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.5 Latin America Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.5.1 Brazil Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.5.2 Mexico Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.5.3 Argentina Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.5.4 Colombia Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.5.5 Rest of Latin America Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5.6 Top 15 Countries in Peptide Therapy Market by 2031 Value (in USD billion)
6. Key Growth Drivers for Global Peptide Therapy Market
6.1 GLP-1 Global Obesity Epidemic & Disease Burden
6.2 Regulatory Milestone Cascade Creating New Market Segments
6.3 PRRT and Radioligand Peptide Oncology Expansion
6.4 Next-Generation Peptide Drug Innovation Pipeline
6.5 GLP-1 Biosimilar Volume Expansion in Emerging Markets
6.6 AI-Driven Peptide Drug Discovery Accelerating Pipeline
6.2 Regulatory Milestone Cascade Creating New Market Segments
6.3 PRRT and Radioligand Peptide Oncology Expansion
6.4 Next-Generation Peptide Drug Innovation Pipeline
6.5 GLP-1 Biosimilar Volume Expansion in Emerging Markets
6.6 AI-Driven Peptide Drug Discovery Accelerating Pipeline
7. Key Pain Areas / Growth Inhibitors for Global Peptide Therapy Market
7.1 Affordability & Insurance Coverage Gaps
7.2 API Supply Constraints and Manufacturing Complexity
7.3 Long-Term Safety, Durability & Weight Regain Concerns
7.4 Patent Litigation and Biosimilar Market Entry Complexity
7.5 Geopolitical Risk: BIOSECURE Act and Chinese API Dependency
7.6 Market Concentration Risk - Two-Company Duopoly
7.2 API Supply Constraints and Manufacturing Complexity
7.3 Long-Term Safety, Durability & Weight Regain Concerns
7.4 Patent Litigation and Biosimilar Market Entry Complexity
7.5 Geopolitical Risk: BIOSECURE Act and Chinese API Dependency
7.6 Market Concentration Risk - Two-Company Duopoly
8. Key Players in Global Peptide Therapy - Competitive Landscape and SWOT Analysis
8.1 Novo Nordisk A/S
8.1.1 Novo Nordisk A/S Revenue, Volume, Average Selling Price (ASP) and Gross Margin (2020-2025E)
8.1.2 SWOT Analysis of Novo Nordisk A/S
8.2 Eli Lilly and Company
8.2.1 Eli Lilly and Company Revenue, Volume, Average Selling Price (ASP) and Gross Margin (2020-2025E)
8.2.2 SWOT Analysis of Eli Lilly and Company
8.3 Novartis AG
8.3.1 Novartis AG Revenue, Volume, Average Selling Price (ASP) and Gross Margin (2020-2025E)
8.3.2 SWOT Analysis of Novartis AG
8.4 Ipsen SA
8.4.1 Ipsen SA Revenue, Volume, Average Selling Price (ASP) and Gross Margin (2020-2025E)
8.4.2 SWOT Analysis of Ipsen SA
8.5 AbbVie Inc.
8.5.1 AbbVie Inc. Revenue, Volume, Average Selling Price (ASP) and Gross Margin (2020-2025E)
8.5.2 SWOT Analysis of AbbVie Inc.
8.6 Teva Pharmaceutical Industries
8.6.1 Teva Pharmaceutical Industries Revenue, Volume, Average Selling Price (ASP) and Gross Margin (2020-2025E)
8.6.2 SWOT Analysis of Teva Pharmaceutical Industries
8.7 AstraZeneca plc
8.7.1 AstraZeneca plc Revenue, Volume, Average Selling Price (ASP) and Gross Margin (2020-2025E)
8.7.2 SWOT Analysis of AstraZeneca plc
8.8 Ferring Pharmaceuticals
8.8 Ferring Pharmaceuticals Revenue, Volume, Average Selling Price (ASP) and Gross Margin (2020-2025E)
8.8.2 SWOT Analysis of Ferring Pharmaceuticals
8.9 Pfizer Inc.
8.9.1 Pfizer Inc. Revenue, Volume, Average Selling Price (ASP) and Gross Margin (2020-2025E)
8.9.2 SWOT Analysis of Pfizer Inc.
8.10 Amgen Inc.
8.10.1 Amgen Inc. Revenue, Volume, Average Selling Price (ASP) and Gross Margin (2020-2025E)
8.10.2 SWOT Analysis of Amgen Inc.
8.1.1 Novo Nordisk A/S Revenue, Volume, Average Selling Price (ASP) and Gross Margin (2020-2025E)
8.1.2 SWOT Analysis of Novo Nordisk A/S
8.2 Eli Lilly and Company
8.2.1 Eli Lilly and Company Revenue, Volume, Average Selling Price (ASP) and Gross Margin (2020-2025E)
8.2.2 SWOT Analysis of Eli Lilly and Company
8.3 Novartis AG
8.3.1 Novartis AG Revenue, Volume, Average Selling Price (ASP) and Gross Margin (2020-2025E)
8.3.2 SWOT Analysis of Novartis AG
8.4 Ipsen SA
8.4.1 Ipsen SA Revenue, Volume, Average Selling Price (ASP) and Gross Margin (2020-2025E)
8.4.2 SWOT Analysis of Ipsen SA
8.5 AbbVie Inc.
8.5.1 AbbVie Inc. Revenue, Volume, Average Selling Price (ASP) and Gross Margin (2020-2025E)
8.5.2 SWOT Analysis of AbbVie Inc.
8.6 Teva Pharmaceutical Industries
8.6.1 Teva Pharmaceutical Industries Revenue, Volume, Average Selling Price (ASP) and Gross Margin (2020-2025E)
8.6.2 SWOT Analysis of Teva Pharmaceutical Industries
8.7 AstraZeneca plc
8.7.1 AstraZeneca plc Revenue, Volume, Average Selling Price (ASP) and Gross Margin (2020-2025E)
8.7.2 SWOT Analysis of AstraZeneca plc
8.8 Ferring Pharmaceuticals
8.8 Ferring Pharmaceuticals Revenue, Volume, Average Selling Price (ASP) and Gross Margin (2020-2025E)
8.8.2 SWOT Analysis of Ferring Pharmaceuticals
8.9 Pfizer Inc.
8.9.1 Pfizer Inc. Revenue, Volume, Average Selling Price (ASP) and Gross Margin (2020-2025E)
8.9.2 SWOT Analysis of Pfizer Inc.
8.10 Amgen Inc.
8.10.1 Amgen Inc. Revenue, Volume, Average Selling Price (ASP) and Gross Margin (2020-2025E)
8.10.2 SWOT Analysis of Amgen Inc.
9. Competitive Landscape of Key Players in the Global Peptide Therapy Market
9.1 Revenue Comparison 2020-2025E (Peptide Therapy Drug Sales, USD Million)
9.2 Revenue Growth Analysis: Winners & Laggards
9.3 Product Coverage Matrix
9.4 Geographic Coverage Matrix
9.5 Strategic Capability Benchmarking
9.6 Head-to-Head: Novo Nordisk vs. Eli Lilly - The GLP-1 Duopoly Battle
9.7 Strategic Positioning Framework
9.8 M&A Activity, Partnerships & Strategic Moves (2023-2026)
9.9 Competitive Summary Scorecard
9.2 Revenue Growth Analysis: Winners & Laggards
9.3 Product Coverage Matrix
9.4 Geographic Coverage Matrix
9.5 Strategic Capability Benchmarking
9.6 Head-to-Head: Novo Nordisk vs. Eli Lilly - The GLP-1 Duopoly Battle
9.7 Strategic Positioning Framework
9.8 M&A Activity, Partnerships & Strategic Moves (2023-2026)
9.9 Competitive Summary Scorecard
10. Porter’s Five Forces Analysis of Global Peptide Therapy Market
10.1 Bargaining Power of Suppliers: Low-Medium
10.2 Bargaining Power of Buyers: Medium-High
10.3 Threat of New Entrants: Low
10.4 Threat of Substitution: Low-Medium
10.5 Intensity of Competitive Rivalry: Medium-High
10.2 Bargaining Power of Buyers: Medium-High
10.3 Threat of New Entrants: Low
10.4 Threat of Substitution: Low-Medium
10.5 Intensity of Competitive Rivalry: Medium-High
11. PESTLE Analysis of Global Peptide Therapy Market
11.1 Political (P)
11.2 Economic (E)
11.3 Social (S)
11.4 Technological (T)
11.5 Legal (L)
11.6 Environmental (E)
11.2 Economic (E)
11.3 Social (S)
11.4 Technological (T)
11.5 Legal (L)
11.6 Environmental (E)
List of Exhibits
Notes
Company Information
Company Information
List of Exhibits
Exhibit 1.1 Global Peptide Therapy Market 2026-2031 Infographic
Exhibit 2.1 Forecast of Global Peptide Therapy Market Value 2022-2031 (in USD billion)
Exhibit 2.2 Forecast of Global Peptide Therapy Market Volume 2022-2031 (in Billion Dosage Units)
Exhibit 3.1 Segment by Type Market Share in Global Peptide Therapy Market 2026 (in % and USD billion)
Exhibit 3.2 Segment by Type Market Share in Global Peptide Therapy Market 2026 (in % and Billion Dosage Units)
Exhibit 3.3 Segment by Type Wise Value CAGR Growth Rate in Global Peptide Therapy 2026-2031 (in %)
Exhibit 3.4 Segment by Type Wise Volume CAGR Growth Rate in Global Peptide Therapy 2026-2031 (in %)
Exhibit 3.5 Forecast of Global GLP-1/GIP Receptor Agonist Therapy Market Value 2022-2031 (in USD billion)
Exhibit 3.6 Forecast of Global GLP-1/GIP Receptor Agonist Therapy Market Volume 2022-2031 (in Billion Dosage Units)
Exhibit 3.7 Forecast of Global Somatostatin Analog Therapy Market Value 2022-2031 (in USD billion)
Exhibit 3.8 Forecast of Global Somatostatin Analog Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 3.9 Forecast of Global LHRH Analog / GnRH Therapy Market Value 2022-2031 (in USD billion)
Exhibit 3.10 Forecast of Global LHRH Analog / GnRH Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 3.11 Forecast of Global Hormonal Peptide Therapy Market Value 2022-2031 (in USD billion)
Exhibit 3.12 Forecast of Global Hormonal Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 3.13 Forecast of Global Immunomodulatory Peptide Therapy Market Value 2022-2031 (in USD billion)
Exhibit 3.14 Forecast of Global Immunomodulatory Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 3.15 Forecast of Global Bone & Growth Peptide Therapy Market Value 2022-2031 (in USD billion)
Exhibit 3.16 Forecast of Global Bone & Growth Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 3.17 Forecast of Global Oncology Peptide Therapy Market Value 2022-2031 (in USD billion)
Exhibit 3.18 Forecast of Global Oncology Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 3.19 Forecast of Global Other Peptide Therapies Market Value 2022-2031 (in USD billion)
Exhibit 3.20 Forecast of Global Other Peptide Therapies Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 4.1 Segment by Application Market Share in Global Peptide Therapy Market 2026 (in % and USD billion)
Exhibit 4.2 Segment by Application Market Share in Global Peptide Therapy Market 2026 (in % and Billion Dosage Units)
Exhibit 4.3 Segment by Application Wise Value CAGR Growth Rate in Global Peptide Therapy 2026-2031 (in %)
Exhibit 4.4 Segment by Application Wise Volume CAGR Growth Rate in Global Peptide Therapy 2026-2031 (in %)
Exhibit 4.5 Forecast of Global Diabetes & Obesity Market Value 2022-2031 (in USD billion)
Exhibit 4.6 Forecast of Global Diabetes & Obesity Market Volume 2022-2031 (in Billion Dosage Units)
Exhibit 4.7 Forecast of Global Oncology (Cancer Treatment) Market Value 2022-2031 (in USD billion)
Exhibit 4.8 Forecast of Global Oncology (Cancer Treatment) Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 4.9 Forecast of Global Endocrinology Market Value 2022-2031 (in USD billion)
Exhibit 4.10 Forecast of Global Endocrinology Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 4.11 Forecast of Global reproductive health & urology Market Value 2022-2031 (in USD billion)
Exhibit 4.12 Forecast of Global Reproductive Health & Urology Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 4.13 Forecast of Global Immunology & Transplant Market Value 2022-2031 (in USD billion)
Exhibit 4.14 Forecast of Global Immunology & Transplant Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 4.15 Forecast of Global Bone Metabolism & Mineral Disorders Market Value 2022-2031 (in USD billion)
Exhibit 4.16 Forecast of Global Bone Metabolism & Mineral Disorders Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 4.17 Forecast of Global Rare Diseases & Orphan Conditions Market Value 2022-2031 (in USD billion)
Exhibit 4.18 Forecast of Global Rare Diseases & Orphan Conditions Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 4.19 Forecast of Global Other Applications Market Value 2022-2031 (in USD billion)
Exhibit 4.20 Forecast of Global Other Applications Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 5.1 Region-Wise Market Share in Global Peptide Therapy Market 2026 (in % and USD billion)
Exhibit 5.2 Region-Wise Market Share in Global Peptide Therapy 2026 (in % and Billion Dosage Units)
Exhibit 5.3 Region-Wise Value CAGR Growth Rate in Global Peptide Therapy Market 2026-2031 (in %)
Exhibit 5.4 Region-Wise Volume CAGR Growth Rate in Global Peptide Therapy Market 2026-2031 (in %)
Exhibit 5.5 Forecast of Asia-Pacific Peptide Therapy Market 2026-2031 (in USD billion)
Exhibit 5.6 Forecast of Asia-Pacific Peptide Therapy Market 2026-2031 (in Billion Dosage Units)
Exhibit 5.7 Country-Wise Value Market Share in Asia-Pacific Peptide Therapy Market 2026 (in % and USD billion)
Exhibit 5.8 Country-Wise Value CAGR Growth Rate in Asia-Pacific Peptide Therapy Market 2026-2031 (in %)
Exhibit 5.9 Country-Wise Volume Market Share in Asia-Pacific Peptide Therapy Market 2026 (in % and Billion Dosage Units)
Exhibit 5.10 Country-Wise Volume CAGR Growth Rate in Asia-Pacific Peptide Therapy Market 2026-2031 (in %)
Exhibit 5.11 Forecast of China Peptide Therapy Market Value 2026-2031 (in USD billion)
Exhibit 5.12 Forecast of China Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 5.13 Forecast of Japan Peptide Therapy Market Value 2026-2031 (in USD billion)
Exhibit 5.14 Forecast of Japan Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 5.15 Forecast of India Peptide Therapy Market Value 2026-2031 (in USD billion)
Exhibit 5.16 Forecast of India Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 5.17 Forecast of South Korea Peptide Therapy Market Value 2026-2031 (in USD billion)
Exhibit 5.18 Forecast of South Korea Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 5.19 Forecast of Australia Peptide Therapy Market Value 2026-2031 (in USD billion)
Exhibit 5.20 Forecast of Australia Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 5.21 Forecast of Rest of Asia Pacific Peptide Therapy Market Value 2026-2031 (in USD billion)
Exhibit 5.22 Forecast of Rest of Asia Pacific Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 5.23 Forecast of North America Peptide Therapy Market 2026-2031 (in USD billion)
Exhibit 5.24 Forecast of North America Peptide Therapy Market 2026-2031 (in Billion Dosage Units)
Exhibit 5.25 Country-Wise Value Market Share in North America Peptide Therapy Market 2026 (in % and USD billion)
Exhibit 5.26 Country-Wise Value CAGR Growth Rate in North America Peptide Therapy Market 2026-2031 (in %)
Exhibit 5.27 Country-Wise Volume Market Share in North America Peptide Therapy Market 2026 (in % and Billion Dosage Units)
Exhibit 5.28 Country-Wise Volume CAGR Growth Rate in North America Peptide Therapy Market 2026-2031 (in %)
Exhibit 5.29 Forecast of USA Peptide Therapy Market Value 2026-2031 (in USD billion)
Exhibit 5.30 Forecast of USA Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 5.31 Forecast of Canada Peptide Therapy Market Value 2026-2031 (in USD billion)
Exhibit 5.32 Forecast of Canada Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 5.33 Forecast of Europe Peptide Therapy Market 2026-2031 (in USD billion)
Exhibit 5.34 Forecast of Europe Peptide Therapy Market 2026-2031 (in Billion Dosage Units)
Exhibit 5.35 Country-Wise Value Market Share in Europe Peptide Therapy Market 2026 (in % and USD billion)
Exhibit 5.36 Country-Wise Value CAGR Growth Rate in Europe Peptide Therapy Market 2026-2031 (in %)
Exhibit 5.37 Country-Wise Volume Market Share in Europe Peptide Therapy Market 2026 (in % and Billion Dosage Units)
Exhibit 5.38 Country-Wise Volume CAGR Growth Rate in Europe Peptide Therapy Market 2026-2031 (in %)
Exhibit 5.39 Forecast of Germany Peptide Therapy Market Value 2026-2031 (in USD billion)
Exhibit 5.40 Forecast of Germany Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 5.41 Forecast of France Peptide Therapy Market Value 2026-2031 (in USD billion)
Exhibit 5.42 Forecast of France Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 5.43 Forecast of United Kingdom Peptide Therapy Market Value 2026-2031 (in USD billion)
Exhibit 5.44 Forecast of United Kingdom Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 5.45 Forecast of Italy Peptide Therapy Market Value 2026-2031 (in USD billion)
Exhibit 5.46 Forecast of Italy Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 5.47 Forecast of Spain Peptide Therapy Market Value 2026-2031 (in USD billion)
Exhibit 5.48 Forecast of Spain Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 5.49 Forecast of Rest of Europe Peptide Therapy Market Value 2026-2031 (in USD billion)
Exhibit 5.50 Forecast of Rest of Europe Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 5.51 Forecast of Middle East & Africa Peptide Therapy Market 2026-2031 (in USD billion)
Exhibit 5.52 Forecast of Middle East & Africa Peptide Therapy Market 2026-2031 (in Billion Dosage Units)
Exhibit 5.53 Country-Wise Value Market Share in Middle East & Africa Peptide Therapy Market 2026 (in % and USD billion)
Exhibit 5.54 Country-Wise Value CAGR Growth Rate in Middle East & Africa Peptide Therapy Market 2026-2031 (in %)
Exhibit 5.55 Country-Wise Volume Market Share in Middle East & Africa Peptide Therapy Market 2026 (in % and Billion Dosage Units)
Exhibit 5.56 Country-Wise Volume CAGR Growth Rate in Middle East & Africa Peptide Therapy Market 2026-2031 (in %)
Exhibit 5.57 Forecast of Saudi Arabia Peptide Therapy Market Value 2026-2031 (in USD billion)
Exhibit 5.58 Forecast of Saudi Arabia Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 5.59 Forecast of UAE Peptide Therapy Market Value 2026-2031 (in USD billion)
Exhibit 5.60 Forecast of UAE Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 5.61 Forecast of Israel Peptide Therapy Market Value 2026-2031 (in USD billion)
Exhibit 5.62 Forecast of Israel Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 5.63 Forecast of South Africa Peptide Therapy Market Value 2026-2031 (in USD billion)
Exhibit 5.64 Forecast of South Africa Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 5.65 Forecast of Turkey Peptide Therapy Market Value 2026-2031 (in USD billion)
Exhibit 5.66 Forecast of Turkey Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 5.67 Forecast of Rest of Middle East & Africa Peptide Therapy Market Value 2026-2031 (in USD billion)
Exhibit 5.68 Forecast of Rest of Middle East & Africa Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 5.69 Forecast of Latin America Peptide Therapy Market 2026-2031 (in USD billion)
Exhibit 5.70 Forecast of Latin America Peptide Therapy Market 2026-2031 (in Billion Dosage Units)
Exhibit 5.71 Country-Wise Value Market Share in Latin America Peptide Therapy Market 2026 (in % and USD billion)
Exhibit 5.72 Country-Wise Value CAGR Growth Rate in Latin America Peptide Therapy Market 2026-2031 (in %)
Exhibit 5.73 Country-Wise Volume Market Share in Latin America Peptide Therapy Market 2026 (in % and Billion Dosage Units)
Exhibit 5.74 Country-Wise Volume CAGR Growth Rate in Latin America Peptide Therapy Market 2026-2031 (in %)
Exhibit 5.75 Forecast of Brazil Peptide Therapy Market Value 2026-2031 (in USD billion)
Exhibit 5.76 Forecast of Brazil Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 5.77 Forecast of Mexico Peptide Therapy Market Value 2026-2031 (in USD billion)
Exhibit 5.78 Forecast of Mexico Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 5.79 Forecast of Argentina Peptide Therapy Market Value 2026-2031 (in USD billion)
Exhibit 5.80 Forecast of Argentina Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 5.81 Forecast of Colombia Peptide Therapy Market Value 2026-2031 (in USD billion)
Exhibit 5.82 Forecast of Colombia Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 5.83 Forecast of Rest of Latin America Peptide Therapy Market Value 2026-2031 (in USD billion)
Exhibit 5.84 Forecast of Rest of Latin America Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 5.85 Top 15 Countries in Peptide Therapy Market by 2031 Value (in USD billion)
Exhibit 8.1 Novo Nordisk A/S Revenue (in USD billion), Volume (in Billion Dosage Units), Average Selling Price (ASP) and Gross Margin (in %) 2020-2025 (est.)
Exhibit 8.2 SWOT Analysis of Novo Nordisk A/S
Exhibit 8.3 Eli Lilly and Company Revenue (in USD billion), Volume (in Billion Dosage Units), Average Selling Price (ASP) and Gross Margin (in %)2020-2025 (est.)
Exhibit 8.4 SWOT Analysis of Eli Lilly and Company
Exhibit 8.5 Novartis AG Revenue (in USD billion), Volume (in Billion Dosage Units), Average Selling Price (ASP) and Gross Margin (in %)2020-2025 (est.)
Exhibit 8.6 SWOT Analysis of Novartis AG
Exhibit 8.7 Ipsen SA Revenue (in USD billion), Volume (in Billion Dosage Units), Average Selling Price (ASP) and Gross Margin (in %)2020-2025 (est.)
Exhibit 8.8 SWOT Analysis of Ipsen SA
Exhibit 8.9 AbbVie Inc. Revenue (in USD billion), Volume (in Billion Dosage Units), Average Selling Price (ASP) and Gross Margin (in %)2020-2025 (est.)
Exhibit 8.10 SWOT Analysis of AbbVie Inc.
Exhibit 8.11 Teva Pharmaceutical Industries Revenue (in USD billion), Volume (in Billion Dosage Units), Average Selling Price (ASP) and Gross Margin (in %)2020-2025 (est.)
Exhibit 8.12 SWOT Analysis of Teva Pharmaceutical Industries
Exhibit 8.13 AstraZeneca plc Revenue (in USD billion), Volume (in Billion Dosage Units), Average Selling Price (ASP) and Gross Margin (in %)2020-2025 (est.)
Exhibit 8.14 SWOT Analysis of AstraZeneca plc
Exhibit 8.15 Ferring Pharmaceuticals Revenue (in USD billion), Volume (in Billion Dosage Units), Average Selling Price (ASP) and Gross Margin (in %)2020-2025 (est.)
Exhibit 8.16 SWOT Analysis of Ferring Pharmaceuticals
Exhibit 8.17 Pfizer Inc. Revenue (in USD billion), Volume (in Billion Dosage Units), Average Selling Price (ASP) and Gross Margin (in %)2020-2025 (est.)
Exhibit 8.18 SWOT Analysis of Pfizer Inc.
Exhibit 8.19 Amgen Inc. Revenue (in USD billion), Volume (in Billion Dosage Units), Average Selling Price (ASP) and Gross Margin (in %)2020-2025 (est.)
Exhibit 8.20 SWOT Analysis of Amgen Inc.
Exhibit 9.1 Competitive Landscape of Key Players in the Global Peptide Therapy Market
Exhibit 12.1 SWOT Analysis of Global Peptide Therapy Market
Exhibit 13.1 Key Future Trends of Global Peptide Therapy Market
Exhibit 2.1 Forecast of Global Peptide Therapy Market Value 2022-2031 (in USD billion)
Exhibit 2.2 Forecast of Global Peptide Therapy Market Volume 2022-2031 (in Billion Dosage Units)
Exhibit 3.1 Segment by Type Market Share in Global Peptide Therapy Market 2026 (in % and USD billion)
Exhibit 3.2 Segment by Type Market Share in Global Peptide Therapy Market 2026 (in % and Billion Dosage Units)
Exhibit 3.3 Segment by Type Wise Value CAGR Growth Rate in Global Peptide Therapy 2026-2031 (in %)
Exhibit 3.4 Segment by Type Wise Volume CAGR Growth Rate in Global Peptide Therapy 2026-2031 (in %)
Exhibit 3.5 Forecast of Global GLP-1/GIP Receptor Agonist Therapy Market Value 2022-2031 (in USD billion)
Exhibit 3.6 Forecast of Global GLP-1/GIP Receptor Agonist Therapy Market Volume 2022-2031 (in Billion Dosage Units)
Exhibit 3.7 Forecast of Global Somatostatin Analog Therapy Market Value 2022-2031 (in USD billion)
Exhibit 3.8 Forecast of Global Somatostatin Analog Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 3.9 Forecast of Global LHRH Analog / GnRH Therapy Market Value 2022-2031 (in USD billion)
Exhibit 3.10 Forecast of Global LHRH Analog / GnRH Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 3.11 Forecast of Global Hormonal Peptide Therapy Market Value 2022-2031 (in USD billion)
Exhibit 3.12 Forecast of Global Hormonal Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 3.13 Forecast of Global Immunomodulatory Peptide Therapy Market Value 2022-2031 (in USD billion)
Exhibit 3.14 Forecast of Global Immunomodulatory Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 3.15 Forecast of Global Bone & Growth Peptide Therapy Market Value 2022-2031 (in USD billion)
Exhibit 3.16 Forecast of Global Bone & Growth Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 3.17 Forecast of Global Oncology Peptide Therapy Market Value 2022-2031 (in USD billion)
Exhibit 3.18 Forecast of Global Oncology Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 3.19 Forecast of Global Other Peptide Therapies Market Value 2022-2031 (in USD billion)
Exhibit 3.20 Forecast of Global Other Peptide Therapies Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 4.1 Segment by Application Market Share in Global Peptide Therapy Market 2026 (in % and USD billion)
Exhibit 4.2 Segment by Application Market Share in Global Peptide Therapy Market 2026 (in % and Billion Dosage Units)
Exhibit 4.3 Segment by Application Wise Value CAGR Growth Rate in Global Peptide Therapy 2026-2031 (in %)
Exhibit 4.4 Segment by Application Wise Volume CAGR Growth Rate in Global Peptide Therapy 2026-2031 (in %)
Exhibit 4.5 Forecast of Global Diabetes & Obesity Market Value 2022-2031 (in USD billion)
Exhibit 4.6 Forecast of Global Diabetes & Obesity Market Volume 2022-2031 (in Billion Dosage Units)
Exhibit 4.7 Forecast of Global Oncology (Cancer Treatment) Market Value 2022-2031 (in USD billion)
Exhibit 4.8 Forecast of Global Oncology (Cancer Treatment) Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 4.9 Forecast of Global Endocrinology Market Value 2022-2031 (in USD billion)
Exhibit 4.10 Forecast of Global Endocrinology Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 4.11 Forecast of Global reproductive health & urology Market Value 2022-2031 (in USD billion)
Exhibit 4.12 Forecast of Global Reproductive Health & Urology Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 4.13 Forecast of Global Immunology & Transplant Market Value 2022-2031 (in USD billion)
Exhibit 4.14 Forecast of Global Immunology & Transplant Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 4.15 Forecast of Global Bone Metabolism & Mineral Disorders Market Value 2022-2031 (in USD billion)
Exhibit 4.16 Forecast of Global Bone Metabolism & Mineral Disorders Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 4.17 Forecast of Global Rare Diseases & Orphan Conditions Market Value 2022-2031 (in USD billion)
Exhibit 4.18 Forecast of Global Rare Diseases & Orphan Conditions Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 4.19 Forecast of Global Other Applications Market Value 2022-2031 (in USD billion)
Exhibit 4.20 Forecast of Global Other Applications Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 5.1 Region-Wise Market Share in Global Peptide Therapy Market 2026 (in % and USD billion)
Exhibit 5.2 Region-Wise Market Share in Global Peptide Therapy 2026 (in % and Billion Dosage Units)
Exhibit 5.3 Region-Wise Value CAGR Growth Rate in Global Peptide Therapy Market 2026-2031 (in %)
Exhibit 5.4 Region-Wise Volume CAGR Growth Rate in Global Peptide Therapy Market 2026-2031 (in %)
Exhibit 5.5 Forecast of Asia-Pacific Peptide Therapy Market 2026-2031 (in USD billion)
Exhibit 5.6 Forecast of Asia-Pacific Peptide Therapy Market 2026-2031 (in Billion Dosage Units)
Exhibit 5.7 Country-Wise Value Market Share in Asia-Pacific Peptide Therapy Market 2026 (in % and USD billion)
Exhibit 5.8 Country-Wise Value CAGR Growth Rate in Asia-Pacific Peptide Therapy Market 2026-2031 (in %)
Exhibit 5.9 Country-Wise Volume Market Share in Asia-Pacific Peptide Therapy Market 2026 (in % and Billion Dosage Units)
Exhibit 5.10 Country-Wise Volume CAGR Growth Rate in Asia-Pacific Peptide Therapy Market 2026-2031 (in %)
Exhibit 5.11 Forecast of China Peptide Therapy Market Value 2026-2031 (in USD billion)
Exhibit 5.12 Forecast of China Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 5.13 Forecast of Japan Peptide Therapy Market Value 2026-2031 (in USD billion)
Exhibit 5.14 Forecast of Japan Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 5.15 Forecast of India Peptide Therapy Market Value 2026-2031 (in USD billion)
Exhibit 5.16 Forecast of India Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 5.17 Forecast of South Korea Peptide Therapy Market Value 2026-2031 (in USD billion)
Exhibit 5.18 Forecast of South Korea Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 5.19 Forecast of Australia Peptide Therapy Market Value 2026-2031 (in USD billion)
Exhibit 5.20 Forecast of Australia Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 5.21 Forecast of Rest of Asia Pacific Peptide Therapy Market Value 2026-2031 (in USD billion)
Exhibit 5.22 Forecast of Rest of Asia Pacific Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 5.23 Forecast of North America Peptide Therapy Market 2026-2031 (in USD billion)
Exhibit 5.24 Forecast of North America Peptide Therapy Market 2026-2031 (in Billion Dosage Units)
Exhibit 5.25 Country-Wise Value Market Share in North America Peptide Therapy Market 2026 (in % and USD billion)
Exhibit 5.26 Country-Wise Value CAGR Growth Rate in North America Peptide Therapy Market 2026-2031 (in %)
Exhibit 5.27 Country-Wise Volume Market Share in North America Peptide Therapy Market 2026 (in % and Billion Dosage Units)
Exhibit 5.28 Country-Wise Volume CAGR Growth Rate in North America Peptide Therapy Market 2026-2031 (in %)
Exhibit 5.29 Forecast of USA Peptide Therapy Market Value 2026-2031 (in USD billion)
Exhibit 5.30 Forecast of USA Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 5.31 Forecast of Canada Peptide Therapy Market Value 2026-2031 (in USD billion)
Exhibit 5.32 Forecast of Canada Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 5.33 Forecast of Europe Peptide Therapy Market 2026-2031 (in USD billion)
Exhibit 5.34 Forecast of Europe Peptide Therapy Market 2026-2031 (in Billion Dosage Units)
Exhibit 5.35 Country-Wise Value Market Share in Europe Peptide Therapy Market 2026 (in % and USD billion)
Exhibit 5.36 Country-Wise Value CAGR Growth Rate in Europe Peptide Therapy Market 2026-2031 (in %)
Exhibit 5.37 Country-Wise Volume Market Share in Europe Peptide Therapy Market 2026 (in % and Billion Dosage Units)
Exhibit 5.38 Country-Wise Volume CAGR Growth Rate in Europe Peptide Therapy Market 2026-2031 (in %)
Exhibit 5.39 Forecast of Germany Peptide Therapy Market Value 2026-2031 (in USD billion)
Exhibit 5.40 Forecast of Germany Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 5.41 Forecast of France Peptide Therapy Market Value 2026-2031 (in USD billion)
Exhibit 5.42 Forecast of France Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 5.43 Forecast of United Kingdom Peptide Therapy Market Value 2026-2031 (in USD billion)
Exhibit 5.44 Forecast of United Kingdom Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 5.45 Forecast of Italy Peptide Therapy Market Value 2026-2031 (in USD billion)
Exhibit 5.46 Forecast of Italy Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 5.47 Forecast of Spain Peptide Therapy Market Value 2026-2031 (in USD billion)
Exhibit 5.48 Forecast of Spain Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 5.49 Forecast of Rest of Europe Peptide Therapy Market Value 2026-2031 (in USD billion)
Exhibit 5.50 Forecast of Rest of Europe Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 5.51 Forecast of Middle East & Africa Peptide Therapy Market 2026-2031 (in USD billion)
Exhibit 5.52 Forecast of Middle East & Africa Peptide Therapy Market 2026-2031 (in Billion Dosage Units)
Exhibit 5.53 Country-Wise Value Market Share in Middle East & Africa Peptide Therapy Market 2026 (in % and USD billion)
Exhibit 5.54 Country-Wise Value CAGR Growth Rate in Middle East & Africa Peptide Therapy Market 2026-2031 (in %)
Exhibit 5.55 Country-Wise Volume Market Share in Middle East & Africa Peptide Therapy Market 2026 (in % and Billion Dosage Units)
Exhibit 5.56 Country-Wise Volume CAGR Growth Rate in Middle East & Africa Peptide Therapy Market 2026-2031 (in %)
Exhibit 5.57 Forecast of Saudi Arabia Peptide Therapy Market Value 2026-2031 (in USD billion)
Exhibit 5.58 Forecast of Saudi Arabia Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 5.59 Forecast of UAE Peptide Therapy Market Value 2026-2031 (in USD billion)
Exhibit 5.60 Forecast of UAE Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 5.61 Forecast of Israel Peptide Therapy Market Value 2026-2031 (in USD billion)
Exhibit 5.62 Forecast of Israel Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 5.63 Forecast of South Africa Peptide Therapy Market Value 2026-2031 (in USD billion)
Exhibit 5.64 Forecast of South Africa Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 5.65 Forecast of Turkey Peptide Therapy Market Value 2026-2031 (in USD billion)
Exhibit 5.66 Forecast of Turkey Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 5.67 Forecast of Rest of Middle East & Africa Peptide Therapy Market Value 2026-2031 (in USD billion)
Exhibit 5.68 Forecast of Rest of Middle East & Africa Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 5.69 Forecast of Latin America Peptide Therapy Market 2026-2031 (in USD billion)
Exhibit 5.70 Forecast of Latin America Peptide Therapy Market 2026-2031 (in Billion Dosage Units)
Exhibit 5.71 Country-Wise Value Market Share in Latin America Peptide Therapy Market 2026 (in % and USD billion)
Exhibit 5.72 Country-Wise Value CAGR Growth Rate in Latin America Peptide Therapy Market 2026-2031 (in %)
Exhibit 5.73 Country-Wise Volume Market Share in Latin America Peptide Therapy Market 2026 (in % and Billion Dosage Units)
Exhibit 5.74 Country-Wise Volume CAGR Growth Rate in Latin America Peptide Therapy Market 2026-2031 (in %)
Exhibit 5.75 Forecast of Brazil Peptide Therapy Market Value 2026-2031 (in USD billion)
Exhibit 5.76 Forecast of Brazil Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 5.77 Forecast of Mexico Peptide Therapy Market Value 2026-2031 (in USD billion)
Exhibit 5.78 Forecast of Mexico Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 5.79 Forecast of Argentina Peptide Therapy Market Value 2026-2031 (in USD billion)
Exhibit 5.80 Forecast of Argentina Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 5.81 Forecast of Colombia Peptide Therapy Market Value 2026-2031 (in USD billion)
Exhibit 5.82 Forecast of Colombia Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 5.83 Forecast of Rest of Latin America Peptide Therapy Market Value 2026-2031 (in USD billion)
Exhibit 5.84 Forecast of Rest of Latin America Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
Exhibit 5.85 Top 15 Countries in Peptide Therapy Market by 2031 Value (in USD billion)
Exhibit 8.1 Novo Nordisk A/S Revenue (in USD billion), Volume (in Billion Dosage Units), Average Selling Price (ASP) and Gross Margin (in %) 2020-2025 (est.)
Exhibit 8.2 SWOT Analysis of Novo Nordisk A/S
Exhibit 8.3 Eli Lilly and Company Revenue (in USD billion), Volume (in Billion Dosage Units), Average Selling Price (ASP) and Gross Margin (in %)2020-2025 (est.)
Exhibit 8.4 SWOT Analysis of Eli Lilly and Company
Exhibit 8.5 Novartis AG Revenue (in USD billion), Volume (in Billion Dosage Units), Average Selling Price (ASP) and Gross Margin (in %)2020-2025 (est.)
Exhibit 8.6 SWOT Analysis of Novartis AG
Exhibit 8.7 Ipsen SA Revenue (in USD billion), Volume (in Billion Dosage Units), Average Selling Price (ASP) and Gross Margin (in %)2020-2025 (est.)
Exhibit 8.8 SWOT Analysis of Ipsen SA
Exhibit 8.9 AbbVie Inc. Revenue (in USD billion), Volume (in Billion Dosage Units), Average Selling Price (ASP) and Gross Margin (in %)2020-2025 (est.)
Exhibit 8.10 SWOT Analysis of AbbVie Inc.
Exhibit 8.11 Teva Pharmaceutical Industries Revenue (in USD billion), Volume (in Billion Dosage Units), Average Selling Price (ASP) and Gross Margin (in %)2020-2025 (est.)
Exhibit 8.12 SWOT Analysis of Teva Pharmaceutical Industries
Exhibit 8.13 AstraZeneca plc Revenue (in USD billion), Volume (in Billion Dosage Units), Average Selling Price (ASP) and Gross Margin (in %)2020-2025 (est.)
Exhibit 8.14 SWOT Analysis of AstraZeneca plc
Exhibit 8.15 Ferring Pharmaceuticals Revenue (in USD billion), Volume (in Billion Dosage Units), Average Selling Price (ASP) and Gross Margin (in %)2020-2025 (est.)
Exhibit 8.16 SWOT Analysis of Ferring Pharmaceuticals
Exhibit 8.17 Pfizer Inc. Revenue (in USD billion), Volume (in Billion Dosage Units), Average Selling Price (ASP) and Gross Margin (in %)2020-2025 (est.)
Exhibit 8.18 SWOT Analysis of Pfizer Inc.
Exhibit 8.19 Amgen Inc. Revenue (in USD billion), Volume (in Billion Dosage Units), Average Selling Price (ASP) and Gross Margin (in %)2020-2025 (est.)
Exhibit 8.20 SWOT Analysis of Amgen Inc.
Exhibit 9.1 Competitive Landscape of Key Players in the Global Peptide Therapy Market
Exhibit 12.1 SWOT Analysis of Global Peptide Therapy Market
Exhibit 13.1 Key Future Trends of Global Peptide Therapy Market
Companies Mentioned
- Novo Nordisk A/S
- Eli Lilly and Company
- Novartis AG
- Ipsen SA
- AbbVie Inc.
- AstraZeneca plc
- Pfizer Inc.
- Ferring Pharmaceuticals
- Teva Pharmaceutical Industries
- Amgen Inc.
